Pathophysiology and treatment of cystinuria

Nature Reviews Nephrology

Volumn 6, Issue 7, 2010, Pages 424-434

  Chillarón, Josep ^a   Font Llitjós, Mariona ^b   Fort, Joana ^c   Zorzano, Antonio ^c   Goldfarb, David S ^d   Nunes, Virginia ^a   Palacín, Manuel ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CYSTINE; PENICILLAMINE; TIOPRONIN;

ALKALINIZATION; AMINO ACID TRANSPORT; CYSTINURIA; DISEASE CLASSIFICATION; EPITHELIUM CELL; EXTRACORPOREAL LITHOTRIPSY; FLUID INTAKE; GENE MUTATION; HUMAN; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; NEPHROLITHIASIS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; URINE PH; ANIMAL; GENETICS; PATHOPHYSIOLOGY; SECONDARY PREVENTION; URINARY CALCULI;

ANIMALS; CYSTINURIA; HUMANS; RECURRENCE; URINARY CALCULI; SECONDARY PREVENTION;

EID: 77954243756     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.69     Document Type: Review

References (140)

1. Cystinuria Online Mendelian Inheritance in Man® [online], http://www.ncbi.nlm.nih.gov/entrez/ dispomim.cgi?id=220100.
2. Garrod, A. E. Inborn errors of metabolism (lectures I-IV). Lancet 2, 1-214 (1908).
3. Palacín, M., Goodyer, P., Nunes, V. & Gasparini, P. in Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. R., Beaudet, A. L., Sly, S. w. & Valle, D.) 4909-4932 (McGraw-Hill, New York, 2001).
4. Palacín, M., Borsani, G. & Sebastio, G. The molecular bases of cystinuria and lysinuric protein intolerance. Curr. Opin. Genet. Dev. 11, 328-335 (2001).
5. Thier, S., Fox, M., Segal, S. & Rosenberg, L. E. Cystinuria: in vitro demonstration of an intestinal transport defect. Science 143, 482-484 (1964).
6. Thier, S. O., Segal, S., Fox, M., Blair, A. & Rosenberg, L. E. Cystinuria: defective intestinal transport of dibasic amino acids and cystine. J. Clin. Invest. 44, 442-448 (1965).
7. Rosenberg, L. E., Durant, J. L. & Holland, J. M. Intestinal absorption and renal extraction of cystine and cysteine in cystinuria. N. Engl. J. Med. 273, 1239-1245 (1965).
8. Milliner, D. S. & Murphy, M. E. Urolithiasis in pediatric patients. Mayo Clin. Proc. 68, 241-248 (1993).
9. Daniel, H. Molecular and integrative physiology of intestinal peptide transport. Annu. Rev. Physiol. 66, 361-384 (2004). (Pubitemid 40614448)
10. Pras, E. et al. Localization of a gene causing cystinuria to chromosome 2p. Nat. Genet. 6, 415-419 (1994).
11. Calonge, M. J. et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat. Genet. 6, 420-425 (1994).
12. Calonge, M. J. et al. Genetic heterogeneity in cystinuria: the SLC3A1 gene is linked to type I but not to type III cystinuria. Proc. Natl Acad. Sci. USA 92, 9667-9671 (1995).
13. wartenfeld, R. et al. Molecular analysis of cystinuria in Libyan Jews: exclusion of the SLC3A1 gene and mapping of a new locus on 19q. Am. J. Hum. Genet. 60, 617-624 (1997).
14. Bisceglia, L. et al. Localization, by linkage analysis, of the cystinuria type III gene to chromosome 19q13.1. Am. J. Hum. Genet. 60, 611-616 (1997).
15. Feliubadaló, L. et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (b0, +AT) of rBAT. Nat. Genet. 23, 52-57 (1999).
16. Segal, S. & Thier, S. O. in Metabolic and Molecular Bases of Inherited Diseases (eds Scriver, C. H., Beaudet, A. L., Sly, w. S. & Valle, D.) 2479-2496 (McGraw-Hill, New York, 1995).
17. Rosenberg, L. E., Downing, S., Durant, J. L. & Segal, S. Cystinuria: biochemical evidence for three genetically distinct diseases. J. Clin. Invest. 45, 365-371 (1966).
18. Font-Llitjós, M. et al. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. J. Med. Genet. 42, 58-68 (2005).
19. Goodyer, P. R., Clow, C., Reade, T. & Girardin, C. Prospective analysis and classification of patients with cystinuria identified in a newborn screening program. J. Pediatr. 122, 568-572 (1993).
20. Reig, N. et al. The light subunit of system b(0, +) is fully functional in the absence of the heavy subunit. EMBO J. 21, 4906-4914 (2002).
21. Dello Strologo, L. et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. J. Am. Soc. Nephrol. 13, 2547-2553 (2002).
22. Harnevik, L., Fjellstedt, E., Molbaek, A., Denneberg, T. & Söderkvist, P. Mutation analysis of SLC7A9 in cystinuria patients in Sweden. Genet. Test. 7, 13-20 (2003).
23. Brodehl, J., Gellissen, K. & Kowaleski, S. Isolated cystinuria (without lysine-ornithine-argininuria) in a family with hypocalcemia tetany. Klin. Wochenschr. 45, 38 (1967).
24. Eggermann, T., Elbracht, M., Haverkamp, F., Schmidt, C. & Zerres, K. Isolated cystinuria (OMIM 238200) is not a separate entity but is caused by a mutation in the cystinuria gene SLC7A9. Clin. Genet. 71, 597-598 (2007).
25. Parvari, R. et al. A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease. Am. J. Hum. Genet. 69, 869-875 (2001).
26. Jaeken, J. et al. Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia-cystinuria syndrome. Am. J. Hum. Genet. 78, 38-51 (2006).
27. Martens, K. et al. Global distribution of the most prevalent deletions causing hypotonia-cystinuria syndrome. Eur. J. Hum. Genet. 15, 1029-1033 (2007).
28. Chabrol, B. et al. Deletion of C2orf34, PREPL and SLC3A1 causes atypical hypotonia-cystinuria syndrome. J. Med. Genet. 45, 314-318 (2008).
29. Hypotonia-cystinuria syndrome Online Mendelian Inheritance in Man® [online], http://www.ncbi. nlm.nih.gov/entrez/dispomim.cgi?id=606407.
30. Pras, E. et al. Mutations in the SLC3A1 transporter gene in cystinuria. Am. J. Hum. Genet. 56, 1297-1303 (1995).
31. Gitomer, w. L., Reed, B. Y., Ruml, L. A., Sakhaee, K. & Pak, C. Y. Mutations in the genomic deoxyribonucleic acid for SLC3A1 in patients with cystinuria. J. Clin. Endocrinol. Metab. 83, 3688-3694 (1998).
32. Martens, K., Jaeken, J., Matthijs, G. & Creemers, J. w. Multi-system disorder syndromes associated with cystinuria type I. Curr. Mol. Med. 8, 544-550 (2008).
33. Shigeta, Y. et al. A novel missense mutation of SLC7A9 frequent in Japanese cystinuria cases affecting the C-terminus of the transporter. Kidney Int. 69, 1198-1206 (2006).
34. Bisceglia, L. et al. Large rearrangements detected by MLPA, point mutations, and survey of the frequency of mutations within the SLC3A1 and SLC7A9 genes in a cohort of 172 cystinuric Italian patients. Mol. Genet. Metab. 99, 42-52 (2010).
35. Harnevik, L. et al. Identification of 12 novel mutations in the SLC3A1 gene in Swedish cystinuria patients. Hum. Mutat. 18, 516-525 (2001).
36. Pineda, M. et al. The amino acid transporter asc-1 is not involved in cystinuria. Kidney Int. 66, 1453-1464 (2004).
37. Brauers, E., Vester, U., Zerres, K. & Eggermann, T. Search for mutations in SLC1A5 (19q13) in cystinuria patients. J. Inherit. Metab. Dis. 28, 1169-1171 (2005).
38. Schmidt, C. et al. Genetic variations of the SLC7A9 gene: allele distribution of 13 polymorphic sites in German cystinuria patients and controls. Clin. Nephrol. 59, 353-359 (2003).
39. Chatzikyriakidou, A., Sofikitis, N., Kalfakakou, V., Siamopoulos, K. & Georgiou, I. Evidence for association of SLC7A9 gene haplotypes with cystinuria manifestation in SLC7A9 mutation carriers. Urol. Res. 34, 299-303 (2006).
40. DiBartola, S. P., Chew, D. J. & Horton, M. L. Cystinuria in a cat. J. Am. Vet. Med. Assoc. 198, 102-104 (1991).
41. Henthorn, P. S. et al. Canine cystinuria: polymorphism in the canine SLC3A1 gene and identification of a nonsense mutation in cystinuric Newfoundland dogs. Hum. Genet. 107, 295-303 (2000).
42. Bovée, K. C., Bush, M., Dietz, J., Jezyk, P. & Segal, S. Cystinuria in the maned wolf of South America. Science 212, 919-920 (1981).
43. Peters, T. et al. A mouse model for cystinuria type I. Hum. Mol. Genet. 12, 2109-2120 (2003).
44. Feliubadaló, L. et al. SLC7A9-deficient mice develop cystinuria non-I and cystine urolithiasis. Hum. Mol. Genet. 12, 2097-2108 (2003).
45. Verrey, F. et al. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 447, 532-542 (2004).
46. Palacín, M. & Kanai, Y. The ancillary proteins of HATs: SLC3 family of amino acid transporters. Pflugers Arch. 447, 490-494 (2004). (Pubitemid 38241435)
47. Bertran, J. et al. Expression cloning of a cDNA from rabbit kidney cortex that induces a single transport system for cystine and dibasic and neutral amino acids. Proc. Natl Acad. Sci. USA 89, 5601-5605 (1992).
48. Tate, S. S. & Yan, N. & Udenfriend, S. Expression cloning of a Na(+)-independent neutral amino acid transporter from rat kidney. Proc. Natl Acad. Sci. USA 89, 1-5 (1992).
49. Bertran, J. et al. Stimulation of system y(+)-like amino acid transport by the heavy chain of human 4F2 surface antigen in Xenopus laevis oocytes. Proc. Natl Acad. Sci. USA 89, 5606-5610 (1992).
50. wells, R. G., Lee, w. S., Kanai, Y., Leiden, J. M. & Hediger, M. A. The 4F2 antigen heavy chain induces uptake of neutral and dibasic amino acids in Xenopus oocytes. J. Biol. Chem. 267, 15285-15288 (1992).
51. Ohgimoto, S. et al. Molecular characterization of fusion regulatory protein-1 (FRP-1) that induces multinucleated giant cell formation of monocytes and HIV gp160-mediated cell fusion. FRP-1 and 4F2/CD98 are identical molecules. J. Immunol. 155, 3585-3592 (1995).
52. Mastroberardino, L. et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395, 288-291 (1998).
53. Kanai, Y. et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 273, 23629-23632 (1998).
54. Fernández, E., Torrents, D., Zorzano, A., Palacín, M. & Chillarón, J. Identification and functional characterization of a novel low affinity aromatic-preferring amino acid transporter (arpAT). One of the few proteins silenced during primate evolution. J. Biol. Chem. 280, 19364-19372 (2005).
55. Palacín, M. et al. The genetics of heteromeric amino acid transporters. Physiology (Bethesda). 20, 112-124 (2005).
56. Torrents, D. et al. Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. J. Biol. Chem. 273, 32437-32445 (1998).
57. Feral, C. C. et al. CD98hc (SLC3A2) mediates integrin signaling. Proc. Natl Acad. Sci. USA 102, 355-360 (2005).
58. Cantor, J. et al. CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat. Immunol. 10, 412-419 (2009).
59. Fogelstrand, P., Féral, C. C., Zargham, R. & Ginsberg, M. H. Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2). J. Exp. Med. 206, 2397-2406 (2009).
60. Busch, A. E. et al. Opposite directed currents induced by the transport of dibasic and neutral amino acids in Xenopus oocytes expressing the protein rBAT. J. Biol. Chem. 269, 25581-25586 (1994).
61. Chillaron, J. et al. Obligatory amino acid exchange via systems b(0, +)-like and y(+)L-like. A tertiary active transport mechanism for renal reabsorption of cystine and dibasic amino acids. J. Biol. Chem. 271, 17761-17770 (1996).
62. Mora, C. et al. The rBAT gene is responsible for l-cystine uptake via the b(0, +)-like amino acid transport system in a "renal proximal tubular" cell line (OK cells). J. Biol. Chem. 271, 10569-10576 (1996).
63. Munck, B. G. Lysine transport across the small intestine. Stimulating and inhibitory effects of neutral amino acids. J. Membr. Biol. 53, 45-63 (1980).
64. Munck, B. G. Transport of neutral and cationic amino acids across the brush-border membrane of the rabbit ileum. J. Membr. Biol. 83, 1-13 (1985).
65. Fernandez, E. et al. rBAT-b0, +AT heterodimer is the main apical reabsorption system for cystine in the kidney. Am. J. Physiol. Renal Physiol. 283, F540-F548 (2002).
66. Silbernagl, S. The renal handling of amino acids and oligopeptides. Physiol. Rev. 68, 911-1007 (1988).
67. Gabrisko, M. & Janecek, S. Looking for the ancestry of the heavy-chain subunits of heteromeric amino acid transporters rBAT and 4F2hc within the GH13 alpha-amylase family. FEBS J. 276, 7265-7278 (2009).
68. Fort, J. et al. The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane. J. Biol. Chem. 282, 31444-31452 (2007).
69. Ravaud, S. et al. Structural determinants of product specificity of sucrose isomerases. FEBS Lett. 583, 1964-1968 (2009).
70. Hondoh, H. et al. Substrate recognition mechanism of alpha-1, 6-glucosidic linkage hydrolyzing enzyme, dextran glucosidase from Streptococcus mutans. J. Mol. Biol. 378, 913-922 (2008).
71. Shirai, T., Hung, V. S., Morinaka, K., Kobayashi, T. & Ito, S. Crystal structure of GH13 alphaglucosidase GSJ from one of the deepest sea bacteria. Proteins 73, 126-133 (2008).
72. watanabe, K., Hata, Y., Kizaki, H., Katsube, Y. & Suzuki, Y. The refined crystal structure of Bacillus cereus oligo-1,6-glucosidase at 2.0 A resolution: structural characterization of proline-substitution sites for protein thermostabilization. J. Mol. Biol. 269, 142-153 (1997).
73. Zhang, D., Li, N., Lok, S. M., Zhang, L. H. & Swaminathan, K. Isomaltulose synthase (PalI) of Klebsiella sp. LX3. Crystal structure and implication of mechanism. J. Biol. Chem. 278, 35428-35434 (2003).
74. Gasol, E., Jimenez-Vidal, M., Chillaron, J., Zorzano, A. & Palacín, M. Membrane topology of system xc- light subunit reveals a re-entrant loop with substrate-restricted accessibility. J. Biol. Chem. 279, 31228-31236 (2004).
75. Jack, D. L., Paulsen, I. T. & Saier, M. H. Jr. The amino acid/polyamine/organocation (APC) superfamily of transporters specific for amino acids, polyamines and organocations. Microbiology 146, 1797 - 1814 (2000).
76. Reig, N. et al. Functional and structural characterization of the first prokaryotic member of the L-amino acid transporter (LAT) family: a model for APC transporters. J. Biol. Chem. 282, 13270-13281 (2007).
77. Gao, X. et al. Structure and mechanism of an amino acid antiporter. Science 324, 1565-1568 (2009).
78. Fang, Y. et al. Structure of a prokaryotic virtual proton pump at 3.2 A resolution. Nature 460, 1040-1043 (2009).
79. Shaffer, P. L., Goehring, A., Shankaranarayanan, A. & Gouaux, E. Structure and mechanism of a Na+-independent amino acid transporter. Science 325, 1010-1014 (2009).
80. Yamashita, A., Singh, S. K., Kawate, T., Jin, Y. & Gouaux, E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 437, 215-223 (2005).
81. Faham, S. et al. The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. Science 321, 810-814 (2008).
82. weyand, S. et al. Structure and molecular mechanism of a nucleobase-cation-symport-1 family transporter. Science 322, 709-713 (2008).
83. Ressl, S., Terwisscha van Scheltinga, A. C., Vonrhein, C., Ott, V. & Ziegler, C. Molecular basis of transport and regulation in the Na(+)/betaine symporter BetP. Nature 458, 47-52 (2009).
84. Krishnamurthy, H., Piscitelli, C. L. & Gouaux, E. Unlocking the molecular secrets of sodiumcoupled transporters. Nature 459, 347-355 (2009).
85. Gao, X. et al. Mechanism of substrate recognition and transport by an amino acid antiporter. Nature 463, 828-832 (2010).
86. Franca, R., Veljkovic, E., walter, S., wagner, C. A. & Verrey, F. Heterodimeric amino acid transporter glycoprotein domains determining functional subunit association. Biochem. J. 388, 435-443 (2005).
87. Fernández, E. et al. The structural and functional units of heteromeric amino acid transporters. The heavy subunit rBAT dictates oligomerization of the heteromeric amino acid transporters. J. Biol. Chem. 281, 26552-26561 (2006).
88. Sitte, H. H., Farhan, H. & Javitch, J. A. Sodiumdependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. Mol. Interv. 4, 38-47 (2004).
89. Bartoccioni, P., Rius, M., Zorzano, A., Palacín, M. & Chillarón, J. Distinct classes of trafficking rBAT mutants cause the type I cystinuria phenotype. Hum. Mol. Genet. 17, 1845-1854 (2008).
90. Bauch, C. & Verrey, F. Apical heterodimeric cystine and cationic amino acid transporter expressed in MDCK cells. Am. J. Physiol. Renal Physiol. 283, F181-F189 (2002).
91. Sakamoto, S. et al. A novel role of the C-terminus of b0, + AT in the ER-Golgi trafficking of the rBAT-b0, + AT heterodimeric amino acid transporter. Biochem. J. 417, 441-448 (2009).
92. Vembar, S. S. & Brodsky, J. L. One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 9, 944-957 (2008).
93. Pineda, M. et al. Cystinuria-specific rBAT(R365w) mutation reveals two translocation pathways in the amino acid transporter rBAT-b0, +AT. Biochem. J. 377, 665-674 (2004).
94. Font, M. A. et al. Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-Type I cystinuria. Hum. Mol. Genet. 10, 305-316 (2001).
95. Jaeger, P., Portmann, L., Saunders, A., Rosenberg, L. E. & Thier, S. O. Anticystinuric effects of glutamine and of dietary sodium restriction. N. Engl. J. Med. 315, 1120-1123 (1986).
96. Goldfarb, D. S., Coe, F. L. & Asplin, J. R. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 69, 1041-1047 (2006).
97. Rodríguez, L. M., Santos, F., Málaga, S. & Martínez, V. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. Nephron 71, 416-418 (1995).
98. Rodman, J. S. et al. The effect of dietary protein on cystine excretion in patients with cystinuria. Clin. Nephrol. 22, 273-278 (1984).
99. Dent, C. E., Friedman, M., Green, H. & watson, L. C. Treatment of cystinuria. Br. Med. J. 1, 403-408 (1965).
100. Fjellstedt, E., Denneberg, T., Jeppsson, J. O. & Tiselius, H. G. A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. Urol. Res. 29, 295-302 (2001).
101. Sterrett, S. P., Penniston, K. L., wolf, J. S. Jr & Nakada, S. Y. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology 72, 278-281 (2008).
102. Lotz, M. & Bartter, F. C. Stone dissolution with D-penicillamine in cystinuria. Br. Med. J. 2, 1408-1409 (1965).
103. Pak, C. Y., Fuller, C., Sakhaee, K., Zerwekh, J. E. & Adams, B. V. Management of cystine nephrolithiasis with alphamercaptopropionylglycine. J. Urol. 136, 1003-1008 (1986).
104. Font-Llitjós, M. et al. SLC7A9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies. Am. J. Physiol. Renal Physiol. 293, F732-F740 (2007).
105. Nakagawa, Y., Asplin, J. R., Goldfarb, D. S., Parks, J. H. & Coe, F. L. Clinical use of cystine supersaturation measurements. J. Urol. 164, 1481-1485 (2000).
106. Coe, F. L., Clark, C., Parks, J. H. & Asplin, J. R. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J. Urol. 166, 688-693 (2001).
107. Pastore, A. et al. Fully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2- mercaptopropionylglycine in plasma and urine. Clin. Chem. 44, 825-832 (1998).
108. Dello Strologo, L., Laurenzi, C., Legato, A. & Pastore, A. Cystinuria in children and young adults: success of monitoring free-cystine urine levels. Pediatr. Nephrol. 22, 1869-1873 (2007).
109. Preminger, G. M. et al. 2007 Guideline for the management of ureteral calculi. Eur. Urol. 52, 1610-1631 (2007).
110. Bhatta, K. M., Prien, E. L. Jr & Dretler, S. P. Cystine calculi-rough and smooth: a new clinical distinction. J. Urol. 142, 937-940 (1989).
111. Rudnick, D. M., Bennett, P. M. & Dretler, S. P. Retrograde renoscopic fragmentation of moderate-size (1.5-30-cm) renal cystine stones. J. Endourol. 13, 483-485 (1999).
112. Dretler, S. P., Pfister, R. C., Newhouse, J. H. & Prien, E. L. Jr. Percutaneous catheter dissolution of cystine calculi. J. Urol. 131, 216-219 (1984).
113. Chaudhuri, T. K. & Paul, S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J. 273, 1331-1349 (2006).
114. Ringe, D. & Petsko, G. what are pharmacological chaperones and why are they interesting? J. Biol. 8, 80 (2009).
115. Fan, J. Q. & Ishii, S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J. 274, 4962-4971 (2007).
116. Lieberman, R. L. et al. Structure of acid betaglucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat. Chem. Biol. 2, 101-107 (2006).
117. Pey, A. L. et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat. 24, 388-399 (2004).
118. Amaral, M. D. Therapy through chaperones: sense or antisense Cystic fibrosis as a model disease. J. Inherit. Metab. Dis. 29, 477-487 (2006).
119. Ozcan, U. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140 (2006).
120. Parenti, G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med. 1, 268-279 (2009).
121. Bröer, S. Apical transporters for neutral amino acids: physiology and pathophysiology. Physiology (Bethesda) 23, 95-103 (2008).
122. Torrents, D. et al. Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. Nat. Genet. 21, 293-296 (1999).
123. Borsani, G. et al. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat. Genet. 21, 297-301 (1999).
124. Fernández, E. et al. Basolateral LAT-2 has a major role in the transepithelial flux of L-cystine in the renal proximal tubule cell line OK. J. Am. Soc. Nephrol. 14, 837-847 (2003).
125. Ramadan, T. et al. Basolateral aromatic amino acid transporter TAT1 (Slc16a10) functions as an efflux pathway. J. Cell. Physiol. 206, 771-779 (2006).
126. Ramadan, T. et al. Recycling of aromatic amino acids via TAT1 allows efflux of neutral amino acids via LAT2-4F2hc exchanger. Pflugers Arch. 454, 507-516 (2007).
127. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993).
128. Gasparini, P. et al. Molecular genetics of cystinuria: identification of four new mutations and seven polymorphisms, and evidence for genetic heterogeneity. Am. J. Hum. Genet. 57, 781-788 (1995).
129. Bisceglia, L. et al. Molecular analysis of the cystinuria disease gene: identification of four new mutations, one large deletion, and one polymorphism. Hum. Genet. 98, 447-451 (1996).
130. Bisceglia, L. et al. Cystinuria type I: identification of eight new mutations in SLC3A1. Kidney Int. 59, 1250-1256 (2001).
131. Guillén, M. et al. Identification of novel SLC3A1 gene mutations in Spanish cystinuria families and association with clinical phenotypes. Clin. Genet. 67, 240-251 (2005).
132. Di Perna, M. et al. Twenty-four novel mutations identified in a cohort of 85 patients by direct sequencing of the SLC3A1 and SLC7A9 cystinuria genes. Genet. Test. 12, 351-355 (2008).
133. Chatzikyriakidou, A. et al. An overview of SLC3A1 and SLC7A9 mutations in Greek cystinuria patients. Mol. Genet. Metab. 95, 192-193 (2008).
134. Brauers, E. et al. Identification of novel cystinuria mutations in pediatric patients. J. Pediatr. Urol. 2, 575-578 (2006).
135. Saadi, I. et al. Molecular genetics of cystinuria: mutation analysis of SLC3A1 and evidence for another gene in type I (silent) phenotype. Kidney Int. 54, 48-55 (1998).
136. Skopková, Z., Hrabincová, E., Stástná, S., Kozák, L. & Adam, T. Molecular genetic analysis of SLC3A1 and SLC7A9 genes in Czech and Slovak cystinuric patients. Ann. Hum. Genet. 69, 501-507 (2005).
137. Chillarón, J. et al. An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K. J. Biol. Chem. 272, 9543-9549 (1997).
138. Guillén, M., Corella, D., Cabello, M. L., García, A. M. & Hernández-Yago, J. Reference values of urinary excretion of cystine and dibasic aminoacids: classification of patients with cystinuria in the Valencian Community, Spain. Clin. Biochem. 32, 25-30 (1999).
139. Botzenhart, E. et al. Cystinuria in children: distribution and frequencies of mutations in the SLC3A1 and SLC7A9 genes. Kidney Int. 62, 1136-1142 (2002).
140. Leclerc, D. et al. SLC7A9 mutations in all three cystinuria subtypes. Kidney Int. 62, 1550-1559 (2002).